The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis in Gulf Countries
This study aims to assess the impact of dupilumab on the mental health and quality of life of moderate-to-severe Atopic Dermatitis (AD) patients. The study will recruit participants from AD patients who are already receiving dupilumab treatment. The study enrollment period will be about 9 months with each of the participants undergoing a 6-month observational study period.
• Participants who have moderate to severe AD with signs and symptoms of anxiety and/or depression.
• Participants who initiate dupilumab therapy within 30 days of enrolment, based on the treating physician's decision, independently of study participation
• Participants and/or their legally approved representatives (LAR in case of the minor subject) must agree to sign an informed consent or an assent.